tiprankstipranks
Zymeworks Inc (ZYME)
NYSE:ZYME

Zymeworks Stock Analysis & Ratings

ZYME Stock Chart & Stats

Day’s Range$5.17 - $5.845
52-Week Range$4.56 - $39.41
Previous Close$5.88
Volume865.69K
Average Volume (3M)1.56M
Market Cap$296.94M
P/E Ratio-1.3
Beta1.05
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)-4.51


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ZYME FAQ

What was Zymeworks’s price range in the past 12 months?
Zymeworks lowest stock price was $4.56 and its highest was $39.41 in the past 12 months.
    What is Zymeworks’s market cap?
    Zymeworks’s market cap is $296.94M.
      What is Zymeworks’s price target?
      The average price target for Zymeworks is $21.14. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $45.00 ,the lowest forecast is $7.00. The average price target represents 311.28% Increase from the current price of $5.14.
        What do analysts say about Zymeworks?
        Zymeworks’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
          When is Zymeworks’s upcoming earnings report date?
          Zymeworks’s upcoming earnings report date is Aug 03, 2022 which is in 77 days.
            How were Zymeworks’s earnings last quarter?
            Zymeworks released its earnings results on May 04, 2022. The company reported -$1.19 earnings per share for the quarter, missing the consensus estimate of -$0.981 by -$0.209.
              Is Zymeworks overvalued?
              According to Wall Street analysts Zymeworks’s price is currently Undervalued.
                Does Zymeworks pay dividends?
                Zymeworks does not currently pay dividends.
                What is Zymeworks’s EPS estimate?
                Zymeworks’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Zymeworks have?
                Zymeworks has 39,310,000 shares outstanding.
                  What happened to Zymeworks’s price movement after its last earnings report?
                  Zymeworks reported an EPS of -$1.19 in its last earnings report, missing expectations of -$0.981. Following the earnings report the stock price went down -7.681%.
                    Which hedge fund is a major shareholder of Zymeworks?
                    Among the largest hedge funds holding Zymeworks’s share is Perceptive Advisors LLC. It holds Zymeworks’s shares valued at 35M.

                      ---

                      Zymeworks Stock Analysis

                      The Zymeworks stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Zymeworks Inc

                      Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Merck & Company
                      Sorrento Therapeutics
                      Eloxx Pharmaceuticals
                      Eli Lilly & Co
                      Sesen Bio

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis